135 related articles for article (PubMed ID: 27658959)
1. Prolactin receptor in breast cancer: marker for metastatic risk.
Shemanko CS
J Mol Endocrinol; 2016 Nov; 57(4):R153-R165. PubMed ID: 27658959
[TBL] [Abstract][Full Text] [Related]
2. What Is Breast in the Bone?
Shemanko CS; Cong Y; Forsyth A
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27782069
[TBL] [Abstract][Full Text] [Related]
3. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
[TBL] [Abstract][Full Text] [Related]
4. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
5. Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice.
Utama FE; LeBaron MJ; Neilson LM; Sultan AS; Parlow AF; Wagner KU; Rui H
J Endocrinol; 2006 Mar; 188(3):589-601. PubMed ID: 16522738
[TBL] [Abstract][Full Text] [Related]
6. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment.
Yang N; Liu C; Peck AR; Girondo MA; Yanac AF; Tran TH; Utama FE; Tanaka T; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Rui H
Breast Cancer Res; 2013; 15(5):R73. PubMed ID: 24004716
[TBL] [Abstract][Full Text] [Related]
7. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
8. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
9. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
10. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
11. Cells with minimal expression of the JAK/STAT pathway related proteins STAT5a and the prolactin receptor: evidence of an alternate prolactin receptor isoform in breast disease.
Bratthauer GL; Stamatakos MD; Vinh TN
Protein Pept Lett; 2010 Jan; 17(1):104-8. PubMed ID: 20214633
[TBL] [Abstract][Full Text] [Related]
12. Prolactin and the prolactin receptor: new targets of an old hormone.
Harris J; Stanford PM; Oakes SR; Ormandy CJ
Ann Med; 2004; 36(6):414-25. PubMed ID: 15513293
[TBL] [Abstract][Full Text] [Related]
13. Multiple new isoforms of the human prolactin receptor gene.
Trott JF; Hovey RC; Koduri S; Vonderhaar BK
Adv Exp Med Biol; 2004; 554():495-9. PubMed ID: 15384631
[No Abstract] [Full Text] [Related]
14. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
15. Impact of subdomain D1 of the short form S1b of the human prolactin receptor on its inhibitory action on the function of the long form of the receptor induced by prolactin.
Kang JH; Hassan SA; Zhao P; Tsai-Morris CH; Dufau ML
Biochim Biophys Acta; 2014 Jul; 1840(7):2272-80. PubMed ID: 24735798
[TBL] [Abstract][Full Text] [Related]
16. Prolactin and human tumourogenesis.
Fernandez I; Touraine P; Goffin V
J Neuroendocrinol; 2010 Jul; 22(7):771-7. PubMed ID: 20456598
[TBL] [Abstract][Full Text] [Related]
17. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling.
García-Martínez JM; Calcabrini A; González L; Martín-Forero E; Agulló-Ortuño MT; Simon V; Watkin H; Anderson SM; Roche S; Martín-Pérez J
Cell Signal; 2010 Mar; 22(3):415-26. PubMed ID: 19892015
[TBL] [Abstract][Full Text] [Related]
18. Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.
Pignatelli J; Goswami S; Jones JG; Rohan TE; Pieri E; Chen X; Adler E; Cox D; Maleki S; Bresnick A; Gertler FB; Condeelis JS; Oktay MH
Sci Signal; 2014 Nov; 7(353):ra112. PubMed ID: 25429076
[TBL] [Abstract][Full Text] [Related]
19. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
20. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Wu AM; Dalvi P; Lu X; Yang M; Riddick DS; Matthews J; Clevenger CV; Ross DD; Harper PA; Ito S
Mol Pharmacol; 2013 Feb; 83(2):377-88. PubMed ID: 23150485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
